查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1373929

支气管扩张药物市场，按药物类别、给药途径、配销通路、国家和地区 - 2023-2030 年行业分析、市场规模、市场份额和预测

Bronchiectasis Drugs Market, By Drug Class, By Route of Administration, By Distribution Channel, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2023-2030
出版日期: | 出版商: AnalystView Market Insights | 英文 306 Pages | 商品交期: 2-3个工作天内

价格

报告要点

2022年支气管扩张药物市场规模为4.8171亿美元，2023年至2030年复合CAGR为5.1%。

支气管扩张药物市场-市场动态

人们对这种经常被低估的疾病的认识不断提高，推动了市场需求

医学知识和诊断能力的进步导致支气管扩张病例的识别增加。此外，人口老化和慢性呼吸系统疾病的激增增加了对更有效治疗解决方案的需求。这种认识的提高以及患者人数的增加，促使製药公司和研究人员分配资源来制定增强的支气管扩张治疗策略。这些努力背后的驱动力是致力于改善支气管扩张患者的福祉，同时减轻反覆感染和相关症状的负担。

支气管扩张药物市场 - 关键见解

根据我们的研究分析师提供的见解，预计 2023 年至 2030 年的预测期内，全球支气管扩张药物市场的年增长率约为 5.1%。

支气管扩张药物产业有望大幅扩张，这主要是由于人们越来越认识到这种经常未被发现的医疗状况。

就药物类别分类而言，预计抗生素将在 2022 年占据市场主导地位。

在考虑基于给药途径的细分时，口服药物成为 2022 年的主导类别。

从地理上看，北美地区在 2022 年的创收方面处于领先地位。

支气管扩张药物市场-細項分析：

全球支气管扩张药物市场是围绕着药物类别、给药途径、配销通路和地区等关键因素而建构的。

在药物类别分类方面，该市场分为四个不同的部分：抗生素、黏液溶解剂、支气管扩张剂和抗发炎药物。值得注意的是，抗生素在这一分类中处于领先地位。它们在支气管扩张治疗中的重要性在于它们在控制和预防肺部感染復发方面的作用，肺部感染是与此疾病相关的常见併发症。抗生素有助于瞄准和根除导致这些感染的微生物，最终改善患者症状、肺功能和整体生活品质。

支气管扩张药物市场 - 地理洞察

从地理来看，这个市场横跨北美、拉丁美洲、欧洲、亚太、中东和非洲等地区。在这些地区，各国在推动商业活力方面发挥关键作用。

多种因素共同刺激了北美对支气管扩张药物的需求增加。首先，该地区人口老化越来越容易罹患慢性呼吸系统疾病，包括支气管扩张。其次，诊断专业知识和医疗保健从业人员知识的进步导致诊断更加准确和及时，大大增加了对这些药物的需求。

支气管扩张药物市场-竞争格局：

支气管扩张药物市场的特点是批准用于这种疾病的专门治疗方法的选择有限。领先的製药公司提供一些主要的治疗选择。然而，该领域在专门药物方面受到一定限制，治疗主要依靠重新利用的抗生素、支气管扩张剂和黏液溶解剂。这种限制为新药的开发创造了一个利基市场，因为该公司正在探索旨在解决支气管扩张的根本原因并改善患者预后的创新疗法。这为该行业的成长和进步带来了光明的前景。

目录

第 1 章：支气管扩张药物市场概述

  • 研究范围
  • 市场预估年份

第 2 章：执行摘要

  • 市场摘录
    • 按药物类别分類的支气管扩张药物市场摘录
    • 依给药途径分類的支气管扩张药物市场摘录
    • 按配销通路分類的支气管扩张药物市场摘录
    • 按国家/地区分類的支气管扩张药物市场摘录
    • 按地区分類的支气管扩张药物市场摘录
  • 竞争洞察

第 3 章：支气管扩张药物主要市场趋势

  • 支气管扩张药物市场驱动因素
    • 市场驱动因素的影响分析
  • 支气管扩张药物市场限制
    • 市场限制影响分析
  • 支气管扩张药物市场机会
  • 支气管扩张药物市场未来趋势

第 4 章：支气管扩张药物产业研究

  • PEST分析
  • 波特五力分析
  • 成长前景图
  • 规范架构分析

第 5 章：支气管扩张药物市场：COVID-19 影响分析

  • COVID-19 之前的影响分析
  • COVID-19 后影响分析
    • 表现最佳的市场区隔
    • 边际增长部分
    • 最鬆散的部分
    • 边际损失部分

第 6 章：支气管扩张药物市场格局

  • 2022 年支气管扩张药物市占率分析
  • 按主要製造商分類的故障数据
    • 既定玩家分析
    • 新兴玩家分析

第 7 章：支气管扩张药物市场 - 按药物类别

  • 概述
    • 按药物类别分類的细分市场份额分析
    • 抗生素
    • 黏液溶解剂
    • 支气管扩张剂
    • 抗发炎剂

第 8 章：支气管扩张药物市场 - 按给药途径

  • 概述
    • 按给药途径分類的细分市占率分析
    • 口服
    • 吸入
    • 静脉

第 9 章：支气管扩张药物市场 - 按配销通路

  • 概述
    • 按配销通路分類的细分市场份额分析
    • 医院药房
    • 零售药局
    • 网路药局

第 10 章：支气管扩张药物市场 - 按地理位置

  • 介绍
    • 按地理位置分類的细分市场占有率分析
  • 北美洲
    • 概述
    • 北美支气管扩张药物主要製造商
    • 北美市场规模和预测（按国家）
    • 北美市场规模和预测（按药物类别）
    • 北美市场规模与预测（按管理途径）
    • 北美市场规模和预测（按配销通路）
    • 我们
    • 加拿大
  • 欧洲
    • 概述
    • 欧洲支气管扩张药物主要製造商
    • 欧洲市场规模和预测（按国家）
    • 欧洲市场规模和预测（按药物类别）
    • 欧洲市场规模与预测（按管理途径）
    • 欧洲市场规模和预测（按配销通路）
    • 德国
    • 义大利
    • 英国
    • 法国
    • 俄罗斯
    • 荷兰
    • 瑞典
    • 波兰
    • 欧洲其他地区
  • 亚太地区 (APAC)
    • 概述
    • 亚太地区支气管扩张药物主要製造商
    • 亚太地区市场规模与预测（按国家）
    • 亚太地区市场规模和预测（按药物类别）
    • 亚太地区市场规模与预测（依管理途径）
    • 亚太地区市场规模和预测（按配销通路）
    • 印度
    • 中国
    • 日本
    • 韩国
    • 澳洲
    • 泰国
    • 印尼
    • 菲律宾
    • 亚太地区其他地区
  • 拉丁美洲
    • 概述
    • 拉丁美洲支气管扩张药物主要製造商
    • 拉丁美洲市场规模与预测（按国家）
    • 拉丁美洲市场规模与预测（按药物类别）
    • 拉丁美洲市场规模与预测（按管理途径）
    • 拉丁美洲市场规模和预测（按配销通路）
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥伦比亚
    • 拉丁美洲其他地区
  • 中东和非洲
    • 概述
    • 中东和非洲支气管扩张药物主要製造商
    • 中东和非洲市场规模及预测（按国家）
    • 中东和非洲市场规模及预测（按药物类别）
    • 中东和非洲市场规模及预测（按管理途径）
    • 中东和非洲市场规模及预测（按配销通路）
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 以色列
    • 土耳其
    • 阿尔及利亚
    • 埃及
    • MEA 的其余部分

第 11 章：主要供应商分析-支气管扩张药物产业

  • 竞争仪表板
  • 公司简介
    • GlaxoSmithKline plc
    • Novartis AG
    • Pfizer Inc.
    • AstraZeneca plc
    • Boehringer Ingelheim International GmbH
    • Roche Holding AG
    • Teva Pharmaceutical Industries Ltd.
    • Bayer AG
    • Sanofi SA
    • Sunovion Pharmaceuticals Inc.
    • Mylan NV
    • Cipla Ltd.
    • Grifols SA
    • Insmed Incorporated
    • Arbor Pharmaceuticals LLC

第 12 章：360 度分析师视角

第 13 章：附录

  • 研究方法论
  • 参考
  • 缩写
  • 免责声明
  • 联络我们
Product Code: ANV1785

REPORT HIGHLIGHT

Bronchiectasis Drugs Market size was valued at USD 481.71 Million in 2022, expanding at a CAGR of 5.1 % from 2023 to 2030.

Pharmaceutical solutions designed for bronchiectasis address the challenges associated with this persistent lung condition, characterized by the inflammation and enlargement of the bronchial tubes. These medications are tailored to alleviate symptoms such as persistent coughing, excessive mucus production, and the susceptibility to recurring lung infections. Treatment typically includes the administration of antibiotics to combat or prevent infections, bronchodilators to expand air passages, and mucolytics to facilitate mucus clearance. The treatment approach is individualized to cater to the specific needs of each patient, with a primary focus on symptom management, infection prevention, and the enhancement of overall lung function, ultimately aiming to enhance the quality of life for those living with bronchiectasis.

Bronchiectasis Drugs Market- Market Dynamics

Rising awareness of this often-underdiagnosed condition propel market demand

Advances in medical knowledge and diagnostic capabilities have led to an uptick in the identification of bronchiectasis cases. Additionally, the aging demographic and the surge in chronic respiratory ailments have heightened the demand for more effective treatment solutions. This increased awareness, along with a growing patient population, has prompted pharmaceutical companies and researchers to allocate resources towards the development of enhanced strategies for managing bronchiectasis. A driving force behind these endeavors is the commitment to improving the well-being of bronchiectasis patients while lessening the burden of recurrent infections and associated symptoms.

Bronchiectasis Drugs Market- Key Insights

In line with the insights provided by our research analyst, the global market for Bronchiectasis Medications is anticipated to experience an approximate annual growth rate of 5.1% throughout the forecast period from 2023 to 2030.

The Bronchiectasis Drugs sector is poised for substantial expansion, primarily driven by the increasing recognition of a medical condition that often goes undetected.

In terms of Drug Class categorization, Antibiotics were forecasted to dominate the market in the year 2022.

When considering the segmentation based on Route of Administration, Oral medications emerged as the leading category in 2022.

Geographically, North America took the lead in revenue generation in 2022.

Bronchiectasis Drugs Market- Segmentation Analysis:

The worldwide market for Bronchiectasis Medications is structured around key factors including Drug Class, Route of Administration, Distribution Channel, and Region.

When it comes to Drug Class categorization, this market is categorized into four distinct segments: Antibiotics, Mucolytics, Bronchodilators, and Anti-inflammatory agents. Notably, Antibiotics take the lead in this classification. Their significance in bronchiectasis therapy lies in their role in managing and preventing the reoccurrence of lung infections, a common complication associated with the condition. Antibiotics are instrumental in targeting and eradicating the microbes responsible for these infections, ultimately leading to improved patient symptoms, lung function, and overall quality of life.

Bronchiectasis Drugs Market- Geographical Insights

From a geographical perspective, this market spans across the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. Within these regions, individual countries play a pivotal role in driving business dynamics.

Several factors have converged to stimulate the heightened demand for bronchiectasis medications in North America. Firstly, the region's aging population is increasingly susceptible to chronic respiratory ailments, including bronchiectasis. Secondly, the advancement of diagnostic expertise and healthcare practitioners' knowledge has led to more precise and timely diagnoses, significantly contributing to the demand for these medications.

Bronchiectasis Drugs Market- Competitive Landscape:

The bronchiectasis pharmaceutical market is distinguished by a limited selection of specialized treatments approved for this condition. Leading pharmaceutical companies offer some of the primary treatment options. Nevertheless, the field is somewhat limited in terms of specialized medications, with therapy predominantly relying on repurposed antibiotics, bronchodilators, and mucolytics. This limitation has created a niche for the development of new drugs, as companies explore innovative therapeutics designed to address the root causes of bronchiectasis and enhance patient outcomes. This presents promising prospects for growth and advancement within the sector.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL BRONCHIECTASIS DRUGS MARKET KEY PLAYERS

  • GlaxoSmithKline plc
  • Novartis AG
  • Pfizer Inc.
  • AstraZeneca plc
  • Boehringer Ingelheim International GmbH
  • Roche Holding AG
  • Teva Pharmaceutical Industries Ltd.
  • Bayer AG
  • Sanofi S.A.
  • Sunovion Pharmaceuticals Inc.
  • Mylan N.V.
  • Cipla Ltd.
  • Grifols S.A.
  • Insmed Incorporated
  • Arbor Pharmaceuticals LLC

GLOBAL BRONCHIECTASIS DRUGS MARKET, BY DRUG CLASS

  • Antibiotics
  • Mucolytics
  • Bronchodilators
  • Anti-inflammatory agents

GLOBAL BRONCHIECTASIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION

  • Oral
  • Inhalation
  • Intravenous

GLOBAL BRONCHIECTASIS DRUGS MARKET, BY DISTRIBUTION CHANNEL

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

GLOBAL BRONCHIECTASIS DRUGS MARKET, BY REGION

  • North America
  • The U.S.
  • Canada
  • Europe
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Russia
  • Netherlands
  • Sweden
  • Poland
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • South Korea
  • Japan
  • Australia
  • Thailand
  • Indonesia
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Bronchiectasis Drugs Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Bronchiectasis Drugs Market Snippet by Drug Class
    • 2.1.2. Bronchiectasis Drugs Market Snippet by Route of Administration
    • 2.1.3. Bronchiectasis Drugs Market Snippet by Distribution Channel
    • 2.1.4. Bronchiectasis Drugs Market Snippet by Country
    • 2.1.5. Bronchiectasis Drugs Market Snippet by Region
  • 2.2. Competitive Insights

3. Bronchiectasis Drugs Key Market Trends

  • 3.1. Bronchiectasis Drugs Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Bronchiectasis Drugs Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Bronchiectasis Drugs Market Opportunities
  • 3.4. Bronchiectasis Drugs Market Future Trends

4. Bronchiectasis Drugs Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Bronchiectasis Drugs Market: COVID-19 Impact Analysis

  • 5.1. Pre-COVID-19 Impact Analysis
  • 5.2. Post-COVID-19 Impact Analysis
    • 5.2.1. Top Performing Segments
    • 5.2.2. Marginal Growth Segments
    • 5.2.3. Top Looser Segments
    • 5.2.4. Marginal Loss Segments

6. Bronchiectasis Drugs Market Landscape

  • 6.1. Bronchiectasis Drugs Market Share Analysis, 2022
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Bronchiectasis Drugs Market - By Drug Class

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Drug Class, 2022 & 2030 (%)
    • 7.1.2. Antibiotics
    • 7.1.3. Mucolytics
    • 7.1.4. Bronchodilators
    • 7.1.5. Anti-inflammatory agents

8. Bronchiectasis Drugs Market - By Route of Administration

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Route of Administration, 2022 & 2030 (%)
    • 8.1.2. Oral
    • 8.1.3. Inhalation
    • 8.1.4. Intravenous

9. Bronchiectasis Drugs Market - By Distribution Channel

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Distribution Channel, 2022 & 2030 (%)
    • 9.1.2. Hospital Pharmacies
    • 9.1.3. Retail Pharmacies
    • 9.1.4. Online Pharmacies

10. Bronchiectasis Drugs Market- By Geography

  • 10.1. Introduction
    • 10.1.1. Segment Share Analysis, By Geography, 2022 & 2030 (%)
  • 10.2. North America
    • 10.2.1. Overview
    • 10.2.2. Bronchiectasis Drugs Key Manufacturers in North America
    • 10.2.3. North America Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 10.2.4. North America Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 10.2.5. North America Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
    • 10.2.6. North America Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.2.7. U.S.
      • 10.2.7.1. Overview
      • 10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.2.7.3. U.S. Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.2.7.4. U.S. Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 10.2.7.5. U.S. Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.2.8. Canada
      • 10.2.8.1. Overview
      • 10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.2.8.3. Canada Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.2.8.4. Canada Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 10.2.8.5. Canada Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
  • 10.3. Europe
    • 10.3.1. Overview
    • 10.3.2. Bronchiectasis Drugs Key Manufacturers in Europe
    • 10.3.3. Europe Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 10.3.4. Europe Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 10.3.5. Europe Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
    • 10.3.6. Europe Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.3.7. Germany
      • 10.3.7.1. Overview
      • 10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.7.3. Germany Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.3.7.4. Germany Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 10.3.7.5. Germany Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.3.8. Italy
      • 10.3.8.1. Overview
      • 10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.8.3. Italy Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.3.8.4. Italy Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 10.3.8.5. Italy Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.3.9. United Kingdom
      • 10.3.9.1. Overview
      • 10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.9.3. United Kingdom Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.3.9.4. United Kingdom Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 10.3.9.5. United Kingdom Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.3.10. France
      • 10.3.10.1. Overview
      • 10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.10.3. France Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.3.10.4. France Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 10.3.10.5. France Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.3.11. Russia
      • 10.3.11.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.11.2. Russia Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.3.11.3. Russia Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 10.3.11.4. Russia Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.3.12. Netherlands
      • 10.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.12.2. Netherlands Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.3.12.3. Netherlands Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 10.3.12.4. Netherlands Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.3.13. Sweden
      • 10.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.13.2. Sweden Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.3.13.3. Sweden Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 10.3.13.4. Sweden Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.3.14. Poland
      • 10.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.14.2. Poland Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.3.14.3. Poland Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 10.3.14.4. Poland Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.3.15. Rest of Europe
      • 10.3.15.1. Overview
      • 10.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.15.3. Rest of the Europe Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.3.15.4. Rest of the Europe Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 10.3.15.5. Rest of the Europe Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
  • 10.4. Asia Pacific (APAC)
    • 10.4.1. Overview
    • 10.4.2. Bronchiectasis Drugs Key Manufacturers in Asia Pacific
    • 10.4.3. Asia Pacific Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 10.4.4. Asia Pacific Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 10.4.5. Asia Pacific Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
    • 10.4.6. Asia Pacific Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.4.7. India
      • 10.4.7.1. Overview
      • 10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.7.3. India Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.4.7.4. India Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 10.4.7.5. India Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.4.8. China
      • 10.4.8.1. Overview
      • 10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.8.3. China Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.4.8.4. China Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 10.4.8.5. China Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.4.9. Japan
      • 10.4.9.1. Overview
      • 10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.9.3. Japan Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.4.9.4. Japan Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 10.4.9.5. Japan Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.4.10. South Korea
      • 10.4.10.1. Overview
      • 10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.10.3. South Korea Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.4.10.4. South Korea Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 10.4.10.5. South Korea Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.4.11. Australia
      • 10.4.11.1. Overview
      • 10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.11.3. Australia Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.4.11.4. Australia Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 10.4.11.5. Australia Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.4.12. Thailand
      • 10.4.12.1. Overview
      • 10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.12.3. Thailand Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.4.12.4. Thailand Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 10.4.12.5. Thailand Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.4.13. Indonesia
      • 10.4.13.1. Overview
      • 10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.13.3. Indonesia Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.4.13.4. Indonesia Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 10.4.13.5. Indonesia Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.4.14. Philippines
      • 10.4.14.1. Overview
      • 10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.14.3. Philippines Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.4.14.4. Philippines Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 10.4.14.5. Philippines Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.4.15. Rest of APAC
      • 10.4.15.1. Overview
      • 10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.15.3. Rest of APAC Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.4.15.4. Rest of APAC Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 10.4.15.5. Rest of APAC Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
  • 10.5. Latin America
    • 10.5.1. Overview
    • 10.5.2. Bronchiectasis Drugs Key Manufacturers in Latin America
    • 10.5.3. Latin America Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 10.5.4. Latin America Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 10.5.5. Latin America Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
    • 10.5.6. Latin America Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.5.7. Brazil
      • 10.5.7.1. Overview
      • 10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.5.7.3. Brazil Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.5.7.4. Brazil Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 10.5.7.5. Brazil Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.5.8. Mexico
      • 10.5.8.1. Overview
      • 10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.5.8.3. Mexico Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.5.8.4. Mexico Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 10.5.8.5. Mexico Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.5.9. Argentina
      • 10.5.9.1. Overview
      • 10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.5.9.3. Argentina Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.5.9.4. Argentina Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 10.5.9.5. Argentina Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.5.10. Colombia
      • 10.5.10.1. Overview
      • 10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.5.10.3. Colombia Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.5.10.4. Colombia Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 10.5.10.5. Colombia Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.5.11. Rest of LATAM
      • 10.5.11.1. Overview
      • 10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.5.11.3. Rest of LATAM Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.5.11.4. Rest of LATAM Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 10.5.11.5. Rest of LATAM Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
  • 10.6. Middle East and Africa
    • 10.6.1. Overview
    • 10.6.2. Bronchiectasis Drugs Key Manufacturers in Middle East and Africa
    • 10.6.3. Middle East and Africa Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 10.6.4. Middle East and Africa Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 10.6.5. Middle East and Africa Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
    • 10.6.6. Middle East and Africa Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.6.7. Saudi Arabia
      • 10.6.7.1. Overview
      • 10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.7.3. Saudi Arabia Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.6.7.4. Saudi Arabia Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 10.6.7.5. Saudi Arabia Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.6.8. United Arab Emirates
      • 10.6.8.1. Overview
      • 10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.8.3. United Arab Emirates Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.6.8.4. United Arab Emirates Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 10.6.8.5. United Arab Emirates Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.6.9. Israel
      • 10.6.9.1. Overview
      • 10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.9.3. Israel Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.6.9.4. Israel Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 10.6.9.5. Israel Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.6.10. Turkey
      • 10.6.10.1. Overview
      • 10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.10.3. Turkey Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.6.10.4. Turkey Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 10.6.10.5. Turkey Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.6.11. Algeria
      • 10.6.11.1. Overview
      • 10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.11.3. Algeria Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.6.11.4. Algeria Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 10.6.11.5. Algeria Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.6.12. Egypt
      • 10.6.12.1. Overview
      • 10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.12.3. Egypt Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.6.12.4. Egypt Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 10.6.12.5. Egypt Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.6.13. Rest of MEA
      • 10.6.13.1. Overview
      • 10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.13.3. Rest of MEA Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.6.13.4. Rest of MEA Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 10.6.13.5. Rest of MEA Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)

11. Key Vendor Analysis- Bronchiectasis Drugs Industry

  • 11.1. Competitive Dashboard
  • 11.2. Company Profiles
    • 11.2.1. GlaxoSmithKline plc
    • 11.2.2. Novartis AG
    • 11.2.3. Pfizer Inc.
    • 11.2.4. AstraZeneca plc
    • 11.2.5. Boehringer Ingelheim International GmbH
    • 11.2.6. Roche Holding AG
    • 11.2.7. Teva Pharmaceutical Industries Ltd.
    • 11.2.8. Bayer AG
    • 11.2.9. Sanofi S.A.
    • 11.2.10. Sunovion Pharmaceuticals Inc.
    • 11.2.11. Mylan N.V.
    • 11.2.12. Cipla Ltd.
    • 11.2.13. Grifols S.A.
    • 11.2.14. Insmed Incorporated
    • 11.2.15. Arbor Pharmaceuticals LLC

12. 360 Degree Analyst View

13. Appendix

  • 13.1. Research Methodology
  • 13.2. References
  • 13.3. Abbreviations
  • 13.4. Disclaimer
  • 13.5. Contact Us

List of Tables

  • TABLE List of data Route of Administrations
  • TABLE Market drivers; Impact Analysis
  • TABLE Market restraints; Impact Analysis
  • TABLE Bronchiectasis Drugs Market: Drug Class Snapshot (2022)
  • TABLE Segment Dashboard; Definition and Scope, by Drug Class
  • TABLE Global Bronchiectasis Drugs Market, by Drug Class 2018-2030 (USD Million)
  • TABLE Bronchiectasis Drugs Market: Route of Administration Snapshot (2022)
  • TABLE Segment Dashboard; Definition and Scope, by Route of Administration
  • TABLE Global Bronchiectasis Drugs Market, by Route of Administration 2018-2030 (USD Million)
  • TABLE Bronchiectasis Drugs Market: Distribution Channel Snapshot (2022)
  • TABLE Segment Dashboard; Definition and Scope, by Distribution Channel
  • TABLE Global Bronchiectasis Drugs Market, by Distribution Channel 2018-2030 (USD Million)
  • TABLE Bronchiectasis Drugs Market: Regional snapshot (2022)
  • TABLE Segment Dashboard; Definition and Scope, by Region
  • TABLE Global Bronchiectasis Drugs Market, by Region 2018-2030 (USD Million)
  • TABLE North America Bronchiectasis Drugs Market, by Country, 2018-2030 (USD Million)
  • TABLE North America Bronchiectasis Drugs Market, by Drug Class, 2018-2030 (USD Million)
  • TABLE North America Bronchiectasis Drugs Market, by Route of Administration, 2018-2030 (USD Million)
  • TABLE North America Bronchiectasis Drugs Market, by Distribution Channel, 2018-2030 (USD Million)
  • TABLE Europe Bronchiectasis Drugs Market, by Country, 2018-2030 (USD Million)
  • TABLE Europe Bronchiectasis Drugs Market, by Drug Class, 2018-2030 (USD Million)
  • TABLE Europe Bronchiectasis Drugs Market, by Route of Administration, 2018-2030 (USD Million)
  • TABLE Europe Bronchiectasis Drugs Market, by Distribution Channel, 2018-2030 (USD Million)
  • TABLE Asia Pacific Bronchiectasis Drugs Market, by Country, 2018-2030 (USD Million)
  • TABLE Asia Pacific Bronchiectasis Drugs Market, by Drug Class, 2018-2030 (USD Million)
  • TABLE Asia Pacific Bronchiectasis Drugs Market, by Route of Administration, 2018-2030 (USD Million)
  • TABLE Asia Pacific Bronchiectasis Drugs Market, by Distribution Channel, 2018-2030 (USD Million)
  • TABLE Latin America Bronchiectasis Drugs Market, by Country, 2018-2030 (USD Million)
  • TABLE Latin America Bronchiectasis Drugs Market, by Drug Class, 2018-2030 (USD Million)
  • TABLE Latin America Bronchiectasis Drugs Market, by Route of Administration, 2018-2030 (USD Million)
  • TABLE Latin America Bronchiectasis Drugs Market, by Distribution Channel, 2018-2030 (USD Million)
  • TABLE Middle East and Africa Bronchiectasis Drugs Market, by Country, 2018-2030 (USD Million)
  • TABLE Middle East and Africa Bronchiectasis Drugs Market, by Drug Class, 2018-2030 (USD Million)
  • TABLE Middle East and Africa Bronchiectasis Drugs Market, by Route of Administration, 2018-2030 (USD Million)
  • TABLE Middle East and Africa Bronchiectasis Drugs Market, by Distribution Channel, 2018-2030 (USD Million)